{"id":"W4309287965","doi":"10.1080/10428194.2022.2136956","title":"Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cohort; Internal medicine; Lenalidomide; Oncology; Lymphoma; Refractory (planetary science); Clinical endpoint; Adverse effect; Multiple myeloma; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005520104,0.001522379,0.002022562,0.0006835525,0.00195022,0.0002670836,0.0006708092,0.0003481518,0.0002489588],"category_scores_gemma":[0.0001118781,0.001288688,0.0005999869,0.001123698,0.0003493114,0.0004625096,0.0006581944,0.0001682618,0.00006714742],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0171935,"about_ca_system_score_gemma":0.005176039,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001908333,"about_ca_topic_score_gemma":0.00007689207,"domain_scores_codex":[0.9922193,0.0002720084,0.001418605,0.002349011,0.001896071,0.001845048],"domain_scores_gemma":[0.9954736,0.0005547212,0.0006845805,0.001741782,0.000458879,0.001086403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03904041,0.06048672,0.2797222,0.0006019686,0.003431686,0.002665029,0.005527374,0.0001615227,0.000237817,0.000638051,0.02031766,0.5871696],"study_design_scores_gemma":[0.424607,0.0251848,0.4844325,0.0001796799,0.002269997,0.001034614,0.002602627,0.003414845,0.000807045,0.0001346275,0.05354154,0.001790654],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886847,0.0008991163,0.00009652953,0.0002070539,0.0007165439,0.00624734,0.0005829813,0.0004139828,0.002151809],"genre_scores_gemma":[0.9885116,0.0001252955,0.0008296372,0.001693189,0.0004281008,0.005213769,0.001103578,0.0003406161,0.001754237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5853789,"threshold_uncertainty_score":0.9997525,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008453224238700503,"score_gpt":0.2541884000132351,"score_spread":0.2457351757745346,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}